Abstract: The present invention relates to a combination of (i) a statin, and (ii) a taxane, for simultaneous or sequential use in the treatment of a patient suffering from solid tumor, e.g. a gastric cancer. The present invention also provides a statin, for use in a method for enhancing sensitivity of a patient suffering from a solid tumor to a taxane.
Type:
Grant
Filed:
May 10, 2012
Date of Patent:
December 22, 2015
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite de Bretagne Occidentale
Inventors:
Laurent Corcos, Catherine Le Jossic-Corcos
Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Type:
Grant
Filed:
September 18, 2014
Date of Patent:
December 1, 2015
Assignee:
United Therapeutics Corporation
Inventors:
Ken Phares, David Mottola, Roger Jeffs, Michael Wade
Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Abstract: The present intervention generally relates to compositions comprising S-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising S-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an S-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets. Accordingly, one aspect of the present invention relates to administration of S-isomer of alpha-methyl-hydrocinnamic acid, e.g., by oral administration to a subject for the treatment of blood disorders, for example but not limited to, hemaglobinaphthy, thalassemia and aplastic anemia.
Abstract: The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus poisoning in an animal that has been exposed to an organophosphorus compound, by administering a therapeutically effective amount of galantamine or a salt thereof, or a biologically active analog, derivative, fragment or variant thereof.
Type:
Grant
Filed:
August 27, 2008
Date of Patent:
September 15, 2015
Assignees:
UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Inventors:
Edson X. Albuquerque, Michael Adler, Edna F. R. Pereira
Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
Type:
Grant
Filed:
March 13, 2015
Date of Patent:
September 1, 2015
Assignee:
PAR PHARMACEUTICAL, INC.
Inventors:
Vinayagam Kannan, Patrick Irish, Michael Bergren
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
Type:
Grant
Filed:
February 23, 2012
Date of Patent:
August 11, 2015
Assignee:
Novartis AG
Inventors:
Valentina Molteni, Yi Fan, Jon Loren, Jeffrey M. Smith, Brenton T. Flatt
Abstract: This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
Type:
Grant
Filed:
August 20, 2013
Date of Patent:
August 11, 2015
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Thorsten Oost, Dennnis Fiegen, Christian Gnamm, Sandra Handschuh, Stefan Peters, Gerald Juergen Roth
Abstract: A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized. Analog and derivative molecules harbor a range of activities. The novel small molecule and most potent antagonist protects the eukaryote Caenorhabditis elegans from quorum-sensing-mediated killing by the bacterial pathogen Chromobacterium violaceum. The saving of C. elegans demonstrates the use of these molecules as small molecule antimicrobials.
Type:
Grant
Filed:
May 28, 2014
Date of Patent:
July 21, 2015
Assignee:
The Trustees of Princeton University
Inventors:
Bonnie L. Bassler, Lee R. Swem, Scott M. Ulrich, Colleen T. O'Loughlin
Abstract: Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Type:
Grant
Filed:
July 26, 2012
Date of Patent:
July 21, 2015
Assignee:
Acacia Pharma Limited
Inventors:
Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Abstract: In one aspect, the invention relates to substituted bicyclic alkoxy pyrazole analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
June 19, 2013
Date of Patent:
May 12, 2015
Assignee:
Vanderbilt University
Inventors:
P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, José Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Gregor James Macdonald, Han Min Tong, Miguel Angel Pena-Piñón, Manuel Jesús Alcázar-Vaca, José Ignacio Andrés-Gil
Abstract: A pharmaceutical composition which includes a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, contact of the reducing sugar and the compound represented by the general formula (I) or a salt thereof is eliminated.
Abstract: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes the following: (a) one or more unsaturated hydrocarbon monomer species and (b) one or more heteroatom-containing monomer species.
Type:
Grant
Filed:
December 8, 2011
Date of Patent:
March 31, 2015
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Robert E. Richard, Marlene C. Schwarz, Rudolf Faust
Abstract: The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
Type:
Grant
Filed:
September 5, 2008
Date of Patent:
March 10, 2015
Assignee:
US WorldMeds LLC
Inventors:
Ahmad Malkawi, Abeer M. Al-Ghananeem, Patrick DeLuca, George A. Digenis
Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Abstract: The invention generally relates to the compositions and methods related to the use of adrenergic receptor agonists solutions for the treatment of skin and mucosal superficial wounds. Some of the preferred adrenergic receptor agonists include epinephrine, phenylephrine, norepinephrine, methoxamine, and mixtures thereof. The invention also relates to devices suitable for applying these solutions to the skin or the mucosal area. Methods according to the invention are especially effective to control superficial skin and mucosal bleeding and accelerate healing time.
Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
Type:
Grant
Filed:
August 13, 2012
Date of Patent:
February 10, 2015
Assignee:
Pivotal Therapeutics Inc.
Inventors:
George Jackowski, Rachelle MacSweeney, Nisar Shaikh, Jason Yantha, Valerie Schini-Kerth